Navigation Links
Interleukin Genetics Reports Fourth Quarter and Year End 2007 Financial Results
Date:3/27/2008

in 2007 over 2006.

Research and development expenses were $2.9 million for the year ended December 31, 2007 compared to $3.3 million for the year ended December 31, 2006, a decrease of $334,000 or 10%. Selling, general and administrative expenses were $6.4 million for the year ended December 31, 2007 compared to $4.5 million for the year ended December 31, 2006, an increase of approximately $1.9 million or 41%. Approximately $1.3 million of this increase resulted from the inclusion of the consumer products segment for the full year 2007 and only since its acquisition in August 2006 in the prior year. Approximately $600,000 of this increase in 2007 resulted from the recording of a potential liability to former employees.

The Company reported a net loss of $6.2 million, or $(0.22) per basic and diluted common share, for the year ended 2007 compared to a net loss of $6.9 million, or $(0.27) per basic and diluted common share in 2006. The decrease was due largely to inclusion of the consumer products segment for the full year 2007, whereas in 2006 that segment was only included since its acquisition on August 17, 2006.

Fourth Quarter Results

Revenue for the three months ended December 31, 2007, was $2.3 million compared to $1.8 million for the same period in 2006. The increase was due largely to increased research revenue in 2007 compared to 2006.

Research and development expenses were $682,000 for the quarter ended December 31, 2007, compared to $1 million for the quarter ended December 31, 2006. The decrease was due largely to a reduction in personnel.

Selling, general and administrative expenses were $1.5 million for the three months ended December 31, 2007, compared to $1.6 million during the same period in the prior year, a decrease of approximately 6%, due largely to a reduction in personnel.

The Company reported a net loss of $1.5 million, or $(0.05) per basic and diluted common share, for the fourth quarter of 200
'/>"/>

SOURCE Interleukin Genetics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. T cell immunity enhanced by timing of interleukin-7 therapy
2. Interleukin Genetics, Inc. Management to Present at Healthcare Conferences
3. Interleukin Genetics to Host Third Quarter 2007 Financial Results Conference Call November 7
4. Genetics Researcher at Childrens Hospital Selected as Howard Hughes Medical Institute Investigator
5. Genetics researcher at Childrens Hospital selected as Howard Hughes Medical Institute Investigator
6. Genetics May Determine Antidepressants Effectiveness
7. Genetics Influence Blood Pressure Medications
8. People with anorexia less likely to be blamed when biology, genetics explained
9. Top10 research advances include studies on genetics and stem cell research, stents
10. Heart attack risk from smoking due to genetics
11. Genetics May Boost Mexican-Americans Risk for Alcoholism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... ... , ... According to Kxan on June 24th a previously FDA ... mice. The study involving isradipine has garnered national attention and is making drug and ... drug and alcohol addictions. The study was conducted by the University of Texas. Human ...
(Date:7/28/2015)... , ... July 28, 2015 , ... Bipolar disorder is ... a day to a few times a year. The World Health Organization (WHO) has ... the National Institute of Mental Health reveals that the United States has the highest ...
(Date:7/28/2015)... Wayne, PA (PRWEB) , ... July 28, 2015 ... ... that its Board of Directors has authorized the Company, from time to time ... with an aggregate value of up to $25 million. Repurchases will be made ...
(Date:7/28/2015)... ... , ... Fertility specialist Dr. Lisa Hasty of Atlanta Center for ... In Atlanta Magazine's annual Top Doctors issue, Dr. Hasty has been recognized for the ... the metro area as one of the most respected doctors in Reproductive Endocrinology. , ...
(Date:7/28/2015)... ... 2015 , ... The PULs Cardiac Test™ identifies asymptomatic patients ... of whom are missed by conventional evaluation , A currently unmet need ... disease, who are at risk of experiencing a coronary event, and for whom ...
Breaking Medicine News(10 mins):Health News:Blood Pressure Medication May be the Key to Treating Addiction 2Health News:Blood Pressure Medication May be the Key to Treating Addiction 3Health News:"I Am Not I" Music Video Raises Bipolar Disorder Awareness 2Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 2Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 3Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 2Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 3Health News:Utility of a novel coronary artery disease biomarker algorithm in modifying physician adherence to guideline therapy presented at 20th World Congress on Heart Disease 2
... supports the theory that bringing about senescence in aged ... ,Inducing senescence in aged cells may be sufficient to ... published online this week in European Molecular Biology Organization ... or programmed cell death – apoptosis – was the ...
... be sufficient to guard against spontaneous cancer development, ... in EMBO reports//. It was previously unknown whether ... – was the more important safeguard mechanism for ... cells have abnormal chromosomes with dysfunctional telomeres – ...
... dead due to the infection of a hospital superbug at ... Clostridium Difficile, commonly known as C diff, within the last ... of the patients were infected with a virulent strain of ... had to be performed on five other patients who had ...
... much of the molecular machinery required for life, are ... all proteins are membrane proteins – embedded within the ... the other two-thirds using such tools as antibodies, they ... portions of proteins. ,To probe the secrets ...
... at the University of Alabama at Birmingham's Magnetic Source ... , using MEG (magneto-encephalography) scanners to learn more about ... types of brain scans detail the geography of the ... the magnetic signals that neurons throw off as they ...
... -- Researchers have identified the receptor pathway used by ... The related report by Hsieh et al, “G protein-coupled ... nongenomic effects of estrogen in attenuating liver injury after ... Journal of Pathology and is accompanied by a commentary. ...
Cached Medicine News:Health News:Penn Scientists Engineer Small Molecules to Probe Proteins Deep Inside Cell Membrane 2Health News:MEG Scanners Are Mega Powerful 2Health News:Estrogen Protects Liver After Traumatic Injury 2
(Date:7/28/2015)... July 28, 2015 Isis Pharmaceuticals, Inc. (NASDAQ: ... a live webcast on Tuesday, August 4 at 11:30 ... financial results and report on pipeline and business progress.  ... call by dialing 877-443-5662 or access the webcast at ... for a limited time at the same address. ...
(Date:7/28/2015)... SOUTH SAN FRANCISCO, Calif. , July 28, ... ) today announced that it will report its ... Tuesday, August 4, 2015.  Rigel senior management will ... and webcast at 4:30pm Eastern Time (1:30pm Pacific ... Participants can access the live conference call by ...
(Date:7/27/2015)... 2015 CTI BioPharma Corp. (NASDAQ and MTA: ... second quarter 2015 financial results on Thursday, August 6, ... Following the announcement, members of the management team will ... and provide a general corporate update at 4:30 p.m. ... be obtained as follows: Thursday, August 6 ...
Breaking Medicine Technology:Webcast Alert: Isis Pharmaceuticals' Second Quarter 2015 Financial Results Conference Call 2Webcast Alert: Isis Pharmaceuticals' Second Quarter 2015 Financial Results Conference Call 3Rigel Announces Conference Call and Webcast to Report Second Quarter 2015 Financial Results 2CTI BioPharma to Report Second Quarter 2015 Financial Results on August 6, 2015 2
... Cell Therapy, Inc. ("Pathfinder")(OTCQB: PFND), a biotechnology company focused ... damage, today announced that effective at the start of ... will change from SYMD to PFND.  The new ticker ... and has been approved by the Financial Industry Regulatory ...
... 2011 Cempra Pharmaceuticals today announced abstracts to ... novel fluoroketolide antibiotic, solithromycin (CEM-101), at the ... (ICAAC) , September 17 to 20, 2011, in ... the safety and routes of administration of CEM-101, ...
Cached Medicine Technology:Pathfinder Cell Therapy, Inc. Announces New Stock Ticker Symbol 2Cempra Pharmaceuticals Presents New Data on its Fourth Generation Macrolide, Solithromycin (CEM-101) at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2Cempra Pharmaceuticals Presents New Data on its Fourth Generation Macrolide, Solithromycin (CEM-101) at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 3Cempra Pharmaceuticals Presents New Data on its Fourth Generation Macrolide, Solithromycin (CEM-101) at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 4Cempra Pharmaceuticals Presents New Data on its Fourth Generation Macrolide, Solithromycin (CEM-101) at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 5
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: